##
##
||||Page|
|---|---|---|---|
|Administrative|and statutory|details||
|Message from the National||Director|2-4|
|Report ofthe|Trustees||5 - 10|
|Independent|Examiners'
report|||
|Accounts comprising:||||
|Statement of|financial activities||12|
|Statement of|financial position|||
|Statement of|cashflows|||
|Notes to the accounts|||15-25|
##
||||ADMINISTRATIVE
AND STATUTORY DETAILS|ADMINISTRATIVE
AND STATUTORY DETAILS|
|---|---|---|---|---|
|Board of|Trustees||Mark Silverman||
||||Gary Fegan||
||||Roger Cockerton (Treasurer)||
||||Dr Tina Flatau||
||||Robert Laid||
||||Simon Dadd||
||||Victoria Penrice||
||||Ellen Lambrix||
|National Director|||Florence Boulton||
|Scientific|Advisory Board||Dame Professor K|Davies —Chair|
||||Professor M Wood|—Vice Chair|
|Registered||office|CAN Mezzanine||
||||49-51 East Road||
||||Hoxton||
||||London||
||||Nl 6AH||
|Independent||Examiners|Simpson Wreford LLP||
||||Wellesley House||
||||Duke ofWellington|Avenue|
||||Royal Arsenal||
||||London||
||||SE186SS||
|Company|number||04899036||
|Charity number|||1101971||
||||SC043S52(Scotland)||
|Solicitors|||Morgan Cole||
||||Bradley Court||
||||Park Place||
||||Cardiff||
||||CF103DR||
|Banks|||Barclays Bank||
||||PO Box3||
||||77North Street,||
||||Keighley||
||||BD213SA||
||||The Co-operative Bank Pic||
||||PO Box250||
||||Skelmersdale||
||||N3 6WT||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||||||12mths to|17mths to|
|---|---|---|---|---|---|---|---|---|
||||||||31March|31March|
|||||2021||2021|2021|2020|
|||||Unresticted||Restricted|Total|Total|
||||Notes|funds||funds|funds|funds|
|Income and endowments||from:|4||||||
|Donations
and legacies||||217,844||5,000|222,844|391,158|
|Charitable
activities||||||125,560|125,560|14,285|
|Other trading activities||||128,874|||128,874|352,763|
|Investments|||||32||32|228|
|Other - Government
grants||||17|028||17028||
|Total income||||3~63|778|~130560|~494338|~758434|
|Expeaditure
on:|||16||||||
|Raising funds:|||||||||
|Cost ofevents and general||fundraising||41,723|||41,723|96,531|
|Charitable activities:|||||||||
|Campaigning
and education||||16,041|||16,041|24,997|
|Scientific and clincial research|||||||||
|and grants payable||||158,255||141,148|299,403|643,779|
|Improved
management|and||||||||
|medical care||||10|694||10694|16665|
|Total expenditure||||~226|713|~141148|~367861|7~81972|
|Net income/(expenditure)||||137,065||(10,588)|126,477|(23,538)|
|Transfers between funds||||~10||10419|||
|Net movement
in funds||||~126|646|~169|~126477|~23538|
|Reconciliation offunds|||||||||
|Balance at I April 2020||||91|600|21428|113028|136566|
|Balance at 31March 2021|||||||||
##
||Notes|Notes|2021||2020||
|---|---|---|---|---|---|---|
|Fixed assets|||||||
|Tangible assets|||1,920|||1,135|
|Investments|||2|||2|
||||1,922|||1,137|
|Current assets|||||||
|Debtors|||51,093|43,867|||
|Cash at bank|and in hand||396747|98374|||
||||447,840|142,241|||
|Current liabilities|||||||
|Creditors
due within one year|||166090|30350|||
|Net current|assets||281 750||111891||
|Total assets|less current liabilities||283,672||113,028||
|Creditors due more than one year||9|44 167||||
|Net assets||15|||11|28|
|Represented|by:||||||
|Restricted funds||13|21,359||21,428||
|Unrestricted|funds|14|218146||91600||
##
||||||12mths to|17mths to|
|---|---|---|---|---|---|---|
||||||31March|31March|
||||||2021|2020|
|||||Notes|Total|Total|
||||||(12)|(17)|
|Csshflows from operating|activities:||||||
|Net cash (used in)/provided
by operating
activities||||19|299765|~87 110|
|Cashflows from investing|activities:||||||
|Dividends,
interest and rents from investments|||||33|228|
|Purchase ofequipment|||||(1,425)||
|Purchase ofinvestments|||||||
|Net cash provided
by/(used|in) investing
activites||||I 392|228|
|Change in cash and cash equivalents
in the reporting|||period||298,373|(86,882)|
|Cash and cash equivalents|as at 1 April 2020|||20|98374|185256|
|Cash and cash equivalents|as at 31March|2021||20|||
##
##
##
##
##
##
|Costs to the company
were as follows:|||
|---|---|---|
||2021|2020|
||(12mths)|(17mths)|
|Gross wages:|||
|- projects|169,635|62,333|
|- non-projects|20,498|210,045|
|Staffpension|4,123|5,687|
|Employer's
NI contributions|14315|23 061|
|||2021|2020|
|---|---|---|---|
|||Number|Number|
|||(12mths)|(17mths)|
|Management
-FTE||0.6||
|Research - FTE||0.6||
|Support - FTE||2.3||
|Fundraising
-FTE||1.8||
|Advocacy/Campaigns|-FTE|0.7||
##
|Net incomia|g resources|is st|ated after c|harging|||
|---|---|---|---|---|---|---|
||||||2021|2020|
||||||(12mths)|(17mths)|
|Independent|examination|snd|accountancy|fees|7,620|8,697|
|Depreciation|||||640|378|
##
##
|||||Unresticted|Restricted|2021|2020|
|---|---|---|---|---|---|---|---|
|||||fuads|funds|Total|Total|
|||||E|K||E|
|||||||(12mtbs)|(17mths)|
||Donations and|legacies||||||
||-Grants ofageneral||nature|13,551|5,000|18,551||
||-Membership
subscriptions|||41,711||41,711|36,614|
||-Fundraising
income|||104,688||104,688|341,830|
||-Gifi Aid|||7,894||7,894|3,736|
||-Other|||50,000||50,000|8,978|
||Charitable
activities|||||||
||-Perfonnance
related||grants||125,560|125,560|14,285|
||-Other|||||||
||Other trading activities|||||||
||-Funraising
events|||4,375||4,375||
||-Non-charitable|trading activities||123,066||123,066|352,763|
||-Shop income|||1,433||1,433||
||Investments|||32||32|228|
||Other —Government||grants|17028||17028||
|||||~7||~44
8||
|5.|Tangible assets|||||||
|||||Computer|Fixtures|Office||
|||||Equipment|dr fittings|equipment|Total|
|||||E||||
||Cost|||||||
||At 1 April 2020|||25,147|1,098|6,839|33,084|
||Additions|||||1 425|1 425|
||31March 2021|||25 147|1098|8264|34509|
||Depreciation|||||||
||At 1 April 2020|||24,161|1,083|6,705|31,949|
||Charge for the year|||246|4|390|640|
||At 31March 2021|||24 407|1087|7095|32589|
||Net book value
At 31March 2021||||||~120|
||At 31March 2020|||||~4|~5|
##
##
|Investments|||||
|---|---|---|---|---|
||||2021|2020|
|Programme|related investments||||
|Converlible|loan note in Halo Therapeutics|LLC|225,000|225,000|
|Less:treated|as grant paid 2012||(224999)|(~224 999|
##
|Debtors|||
|---|---|---|
||2021|2020|
||K||
|Trade debtors|42,858|7,500|
|Other debtors|4,441|9,976|
|Prepayments|3 794|26391|
|||4~3|
##
##
##
|Creditors: amounts
falling due within one year|||
|---|---|---|
||2021|2020|
|Trade creditors|21,426|7,311|
|Accruals and deferred income|137,426|20,655|
|Tax snd social security||47|
|Bank loan|5,833||
|Other creditors|I 405|2337|
##
##
##
##
##
|||Newcastle|Lottery|Science|||
|---|---|---|---|---|---|---|
|||CRF|Fund|on Tour|Demelza|Total|
|At 1April 2020||21,428||||21,428|
|Donations
/ legacies / grants||50,000|75,560||5,000|130,560|
|Grants payable and research|costs|(50,169)|(75,560)|(9,999)|(5,420)|(141,148)|
|Transfers &om unrestricted|funds|||9999|420|10.419|
|As at 31March 2021||||||212|
##
##
|.Unrestricted
funds||
|---|---|
||General|
||fund|
|At 1 April 2020|91,600|
|Income|363,778|
|Expenditure|(226,713)|
|Transfer|~10419|
|At31March2021|21
246|
##
|||Fixed|Current|Current|Long-term||
|---|---|---|---|---|---|---|
|||assets|assets|liabilities|liabiTities|Total|
|||E||||E|
|Restricted funds|||21,259|||21,259|
|Unrestricted|funds|1922|426581|~l66 090|~44167|21R246|
##
##
##
|.Analysis ofresources|expended|||
|---|---|---|---|
|||2021|2020|
||||E|
|||(12mths)|(17mths)|
|Support costs:||||
|Bank charges and interest||1,216|1,317|
|Insurance||1,612|(710)|
|Wages and salaries||208,571|301,126|
|Printing,
postage and|stationery|7,380|6,184|
|Training, recruitment|and other staff costs|3,371|16,497|
|Rent and rates||6,026|38,238|
|Computer costs||10,403|28,303|
|Storage||2,201|1,252|
|Telephone
and internet|costs|2,292|4,280|
|Depreciation||640|378|
|Trustees'
meetings|||7,541|
|Governance costs||15,650|11,467|
|Professional
fees||6,188||
|Miscellaneous
expenditure||1 800|740|
||||Support and|Direct||
|---|---|---|---|---|---|
||||governance|costs|Total|
|Scientific|and clinical|research and||||
|grants payable 80%|||213,880|85,523|299,403|
|Pundraising|10%||26,735|14,988|41,723|
|Campaigning
and education 6%|||16,041||16,041|
|Improved|management|and medical care 4%|10694||10694|
||||2673|||
##
##
|||||2021|2020|
|---|---|---|---|---|---|
||||||E|
|||||(12mths)|(17mths)|
|Grant|—The University ofNewcastle|||50,000|50,000|
|Grant|—CSO||||9,063|
|Grant|—UPPMD|membership|||1,810|
|Grant|—University|Hospitals Bristol NHS Foundation|||12,260|
|Grant|—Queen Mary University||London|25,320||
|Grant|—University|College London|||11,285|
|Grant|—World Duchenne
Organisation|||912||
|Grant|—MD UK||||25 000|
|The following
payments
in res|pe|ct ofresearch|projects have|been committed to|but not prov|ided for in t|
|---|---|---|---|---|---|---|
|accounts:|||||||
||||||2021|2020|
|||||(12mths)||(17mths)|
|Grant to The Univerisity ofNewcastle||||||50,000|
|Grant to Queen Mary University||London||||25 320|
|||||||75 320|
|19.ReconciTiation ofnet income|/|(expenditure)|to net cashflow from operating||activities||
|||||2021||2020|
|||||Total||Total|
||||||E|K|
|||||(12mths)||(17mths)|
|Net surplus/(deficit)
for the reportiag period||||36,476||(23,538)|
|Adjustments
for:|||||||
|Depreciation
charges|||||640|378|
|Dividends,
interest and rents from investments|||||(33)|(228)|
|(Increase) / decrease in debtors|||||(7,226)|40,606|
|Increase / (decrease) in creditors||||169908||~104328|
|Net cash provided
by (used in)||operating activites||2|765||
##
##
||||2021|2020|
|---|---|---|---|---|
||||(12mths)|(17mths)|
|Cash in hand|||396747|98374|
|Total cash and cash equivalents||||~37|
|21.Commitments
under operating|leases||||
|The Charity had annual commitments||under non-cancellable|leases as set out below:||
||||2021|2020|
|||||E|
||||(12mths)|(17mths)|
|Operating
leases which expire: within||two to five years||909|
|22.Loans and overdrafts|||||
||||2021|2020|
||||(12mths)|(17mths)|
|Bank loans|||50000||
|Payable within one year|||5,833||
|Payable after one year|||||
##